{"@context":["https://w3id.org/fdo/context/v1",{"schema":"https://schema.org/","prov":"http://www.w3.org/ns/prov#","fdo":"https://w3id.org/fdo/vocabulary/"}],"@id":"https://fdo.portal.mardi4nfdi.de/fdo/Q2137459","@type":"DigitalObject","kernel":{"@id":"https://fdo.portal.mardi4nfdi.de/fdo/Q2137459","digitalObjectType":"https://schema.org/ScholarlyArticle","primaryIdentifier":"mardi:Q2137459","kernelVersion":"v1","immutable":true,"modified":"2026-01-26T15:23:56Z"},"profile":{"@context":"https://schema.org","@type":"ScholarlyArticle","@id":"https://portal.mardi4nfdi.de/entity/Q2137459","name":"The non-pharmaceutical interventions may affect the advantage in transmission of mutated variants during epidemics: a conceptual model for COVID-19","headline":"The non-pharmaceutical interventions may affect the advantage in transmission of mutated variants during epidemics: a conceptual model for COVID-19","description":"scientific article; zbMATH DE number 7526893","url":"https://portal.mardi4nfdi.de/entity/Q2137459","datePublished":"2022-05-16","author":[{"@id":"https://portal.mardi4nfdi.de/entity/Q1714126"},{"@id":"https://portal.mardi4nfdi.de/entity/Q437583"},{"@id":"https://portal.mardi4nfdi.de/entity/Q2137456"},{"@id":"https://portal.mardi4nfdi.de/entity/Q2043844"},{"@id":"https://portal.mardi4nfdi.de/entity/Q2087510"},{"@id":"https://portal.mardi4nfdi.de/entity/Q2137457"},{"@id":"https://portal.mardi4nfdi.de/entity/Q718763"},{"@id":"https://portal.mardi4nfdi.de/entity/Q2137458"}],"publisher":[{"@id":"https://portal.mardi4nfdi.de/entity/Q69997"}],"identifier":{"@type":"PropertyValue","propertyID":"doi","value":"10.1016/J.JTBI.2022.111105","url":"https://doi.org/10.1016/J.JTBI.2022.111105"},"sameAs":["https://doi.org/10.1016/J.JTBI.2022.111105"],"citation":[{"@id":"https://portal.mardi4nfdi.de/entity/Q1867107"},{"@id":"https://portal.mardi4nfdi.de/entity/Q2038746"}]},"provenance":{"prov:generatedAtTime":"2026-01-26T15:23:56Z","prov:wasAttributedTo":"MaRDI Knowledge Graph"}}